During Tuesday's extended trading session, Celularity Inc. (NASDAQ: CELU) saw a notable uptick in its stock price, gaining 23.57 percent to $7.23 per share. In contrast to CELU's performance during the regular session, which saw a 15.30% loss and close at $5.89, the stock saw a rise in value as traders anticipated a noteworthy development.

Dr. Robert Hariri, M.D., Ph.D., the founder and CEO of Celularity (CELU), will deliver the keynote speech at the Society for Brain Mapping and Therapeutics (SBMT) Annual World Congress on March 16, 2024.

Dr. Hariri's keynote address, "Prospects of Cell and Immunotherapy: From Oncology to Neurodegenerative Pathologies," will examine the wide range of uses for cellular immunotherapy, extending beyond oncological settings to include potential applications in neuroinflammatory and degenerative diseases such as multiple sclerosis and Parkinson's disease.

Additionally, Dr. Hariri will participate in two other keynote panel discussions during the Congress: the first on March 14, focusing on the "Emergence of Neurotech: Convergence of Cellular Therapy, Medical Devices, and Policy," and the second on March 16, exploring the intersection of "Cancer, Neurodegenerative Ailments, and Cellular Interventions."

Within the rapidly evolving landscape of cellular medicine, Celularity is dedicated to advancing transformative therapies for individuals afflicted with neurological ailments, leveraging its proprietary technology platform, which harnesses placental-derived cells, biological materials, and by-products.

Celularity has conducted extensive research in neuroinflammatory conditions, including multiple sclerosis, and has investigated the potential of cellular and regenerative therapies in addressing age-related cognitive decline.

Given the collaborative endeavors facilitated by the SBMT and World Brain Mapping Foundation (WBMF), fostering synergy between academia and industry while presenting viable commercial and investment prospects, the Annual World Congress serves as an ideal forum for discourse on our ongoing research endeavors.

The trajectory of cellular and regenerative medicine is poised for substantial evolution through its convergence with nanotechnology, predictive modeling, advanced devices, imaging techniques, AI integration, and the advent of augmented and virtual reality applications.

Guided by Dr. Hariri's visionary leadership, Celularity is steadfast in its commitment to advancing the frontiers of cellular therapeutics, emerging as a frontrunner in this transformative domain.